AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs

N Yoshida, T Ito, T Karasawa and Z Itoh

Department of Pharmacology, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.

The effects of AS-4370 [4-amino-5-chloro-2-ethoxy-N-(4-(4-fluorobenzyl)- 2 morpholinyl)methyl)benzamide citrate] on gastrointestinal (GI) motor activity were compared with those of cisapride and metoclopramide in conscious dogs with force transducers implanted chronically. In postprandial state, AS-4370 given 0.2 to 1 mg/kg i.v. or 1 mg/kg intraduodenally (i.d.) stimulated the antral and duodenal motor activity without affecting the colonic motor activity. Cisapride at 0.2 to 1 mg/kg i.v. or 1 mg/kg i.d. stimulated the motor activity in all sites of the GI tract from the stomach to the colon simultaneously. Metoclopramide, like AS-4370, stimulated the antral and duodenal motor activity, but its effect was less potent than that of AS-4370. AS-4370 did not stimulate the GI motor activity under treatment with atropine but stimulated it under vagotomy. Furthermore, AS-4370 did not potentiate the methacholine-induced antral contraction, whereas neostigmine at 10 micrograms/kg i.v. significantly enhanced it. AS-4370 at 1 mg/kg i.v. did not antagonize the inhibition of antral motor activity induced by i.v. infusion of dopamine (1 mg/kg/hr), whereas cisapride (0.5 mg/kg i.v.) and metoclopramide (1 mg/kg i.v.) antagonized it. In addition, the enhancement of GI motor activity induced by AS-4370 was not prevented by propranolol, prazosin, yohimbine, methysergide, ketanserin, ICS 205-930 or naloxone. 5- Hydroxytryptamine (5-HT) receptor desensitization induced by 5-HT (300 micrograms/kg/hr) in the antrum reduced the enhancement induced by AS- 4370.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 257, Issue 2, pp. 781-787, 05/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				T. Mikami, Y. Ochi, K. Suzuki, T. Saito, Y. Sugie, and M. Sakakibara 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-{alpha}]pyridine-8-carboxamide (CJ-033,466), a Novel and Selective 5-Hydroxytryptamine4 Receptor Partial Agonist: Pharmacological Profile in Vitro and Gastroprokinetic Effect in Conscious Dogs J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 190 - 199. [Abstract] [Full Text] [PDF]

				T. Tsubouchi, T. Saito, F. Mizutani, T. Yamauchi, and Y. Iwanaga Stimulatory Action of Itopride Hydrochloride on Colonic Motor Activity in Vitro and in Vivo J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 787 - 793. [Abstract] [Full Text] [PDF]

				Y. Mine, T. Yoshikawa, S. Oku, R. Nagai, N. Yoshida, and K. Hosoki Comparison of Effect of Mosapride Citrate and Existing 5-HT4 Receptor Agonists on Gastrointestinal Motility In Vivo and In Vitro J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1000 - 1008. [Abstract] [Full Text]